Cancer Immune Responsiveness Workshop Schedule

Enduring materials from the Cancer Immune Responsiveness Workshop are now available to all attendees. Please click on the following links to access presentations.
Enduring materials will become available to SITC members three months after the program on December 4, 2019.
Enduring materials will become public six months after the program on March 4, 2019.

SITC is committed to sharing presentations from its programs for the advancement of the field but respects faculty requests to maintain confidentiality of their unpublished data and therefore is unable to share presentations with this symbol.

Wednesday, Sept. 4, 2019
7–8 a.m.	Registration and Breakfast
8 a.m.	Opening Remarks Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
Session I: Germline, Somatic Genetics, and Epigenetics of Immune Landscapes
Time:	8:20–9:40 a.m.
Co-Chairs:	Davide Bedognetti, MD, PhD – Sidra Medical and Research Center Josue Samayoa, PhD – AbbVie
8:20 a.m.	Germline Genetic Variation Predicts Immune Signatures in the Cancer Genome Atlas Elad Ziv, MD – University of California San Francisco
8:40 a.m.	Link Between Metastatic Genetic Heterogeneity and the Immune Contexture in Colorectal Cancer Jérôme Galon, PhD – INSERM, Sorbonne Universites Paris
9 a.m.	Germline Biomarkers of Metastatic Melanoma Immunotherapy: Pilot Results of International Consortia Tomas Kirchhoff, PhD – New York University School of Medicine
9:20 a.m.	Mutation Drivers of Immunological Responses to Cancer Eduard Porta, PhD – Barcelona Supercomputing Centre
Session II: Transcriptional Patterns of Distinct Immune Landscapes
Time:	9:40–10:40 a.m.
Co-Chairs:	Yana Najjar, MD – University of Pittsburgh Hua Yu, PhD – City of Hope
9:40 a.m.	STAT3: Targeting Master Regulator of Immune Checkpoints Marcin Kortylewski, PhD – City of Hope
10 a.m.	Immune Gene Expression as a Discovery Tool for Actionable Immunotherapy Resistance Mechanisms Randy F. Sweis, MD – UChicago Medicine
10:20 a.m.	Transcriptional Signatures of Immune Surveillance and a Favorable Tumor Immune Micro-environment Yvonee Saenger, MD – Columbia University/ New York Presbyterian
10:40 a.m.	Break
Session III: Therapeutic Interventions to Modify the Cancer Microenvironment and Related Experimental Systems for Validation
Time:	10:55 a.m.–12:15 p.m.
Co-Chairs:	Rongze Lu, PhD – Abbvie Sarah Warren, PhD – NanoString Technologies, Inc.
10:55 a.m	Radiation Induced Viral Mimicry Sandra Demaria, MD – Weill Cornell Medicine
11:15 a.m.	Development of T cell-based Immunotherapy Against Glioma Antigens Hideho Okada, MD, PhD – University of California San Francisco
11:35 a.m.	Macrophage Immune Checkpoint CD47 is a Novel Therapeutic Target Samuel Henry Cheshier, MD, PhD – University of Utah
11:55 a.m.	Highplex Profiling of Microsatellite Stable and Instable Human Colorectal Carcinoma Karin Pelka, PhD – Broad Institute of MIT and Harvard
12:15–1:15 p.m.	Lunch
Working Group Breakout Sessions
Time:	1:15–4:15 p.m.
Working Group 1:	Germline, Somatic Genetics, and Epigenetics of Immune Landscapes
Co-Chairs:	Davide Bedognetti, MD, PhD – Sidra Medical Josue Samayoa, PhD – AbbVie
Working Group 2:	Transcriptional Patterns of Distinct Immune Landscapes
Co-Chairs:	Yana Najjar, MD – University of Pittsburgh Hua Yu, PhD – City of Hope
Working Group 3:	Therapeutic Interventions to Modify the Cancer Microenvironment and Related Experimental Systems for Validation
Co-Chairs:	Rongze Lu, PhD – Abbvie Sarah Warren, PhD – NanoString Technologies, Inc.
4:15 p.m.	Break
Working Group Presentations
Time:	4:30–6 p.m.
4:30 p.m.	Working Group 1: Germline, Somatic Genetics, and Epigenetics of Immune Landscapes Davide Bedognetti, MD, PhD – Sidra Medical Josue Samayoa, PhD – AbbVie
5 p.m.	Working Group 2: Transcriptional Patterns of Distinct Immune Landscapes Yana Najjar, MD – University of Pittsburgh Hua Yu, PhD – City of Hope
5:30 p.m.	Working Group 3: Therapeutic Interventions to Modify the Cancer Microenvironment and Related Experimental Systems for Validation Rongze Lu, PhD – Abbvie Sarah Warren, PhD – NanoString Technologies, Inc.
6 p.m.	Adjourn

Thursday, Sept. 5, 2019
7–8 a.m.	Registration and Breakfast
8 a.m.	Opening Remarks Franco Marincola, MD – Refuge Biotechnologies
Session I: State of the Field of Adoptive Cellular Therapy
Time:	8:05–9:35 a.m.
Co-Chairs:	Alessandra Cesano, MD, PhD – ESSA Pharma Inc. Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
8:05 a.m.	Introduction Alessandra Cesano, MD, PhD – ESSA Pharma Inc. Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
8:25 a.m.	T cells Recognizing Antigen Through Native or Chimeric Receptors Helen E. Heslop, MD – Baylor College of Medicine
9:15 a.m.	Q&A
9:35 a.m.	Break
Session II: External Circumstantial Factors
Time:	9:50–11:40 a.m.
Co-Chairs:	Alessandra Cesano, MD, PhD – ESSA Pharma Inc. Christine Spencer, PhD – Parker Institute for Cancer Immunotherapy
9:50 a.m.	T cell-intrinsic and -extrinsic Determinants of Response to CAR T cell Therapy J. Joseph Melenhorst, PhD – University of Pennsylvania
10:10 a.m.	Effects of Co-Morbidities and Concomitant Medications on Immunotherapy Efficacy and Safety Michael N. Liebman, PhD – IPQ Analytics, LLC
10:30 a.m.	Learning to Harness Cancer-Curing Poop as a Group: Collaborative Microbiome Research and Beyond at the Parker Institute for Cancer Immunotherapy Christine Spencer, PhD – Parker Institute for Cancer Immunotherapy
10:50 a.m.	Microbiome: Methods and New Technologies for Sample Collection and Assay Standardization Tessa Andermann, MD, MPH – Stanford University
11:10 a.m.	Panel Discussion
11:40 a.m.	Break
Session III: Emerging Ideas and New Concepts
Time:	11:55 a.m.–12:55 p.m.
Co-Chairs:	Francesco M. Marincola, MD – Refuge Biotechnologies, Inc. Kyung-Ho Roh, PhD – University of Alabama in Huntsville
11:55 a.m.	Detection and Activation of CAR-T Cells Using Standardized Models Kyung-Ho Roh, PhD – University of Alabama in Huntsville
12:15 p.m.	Conditional Regulation of CAR T Stanley Qi, PhD – Stanford University
12:35 p.m.	T cell Reprogramming Luca Gattinoni, MD – National Cancer Institute
12:55 p.m.	Lunch
2 p.m.	Cancer Immune Responsiveness Workshop Adjourns
Schedule is subject to change. This program has been supported, in part, by grants from Celgene Corporation, NanoString Technologies, Inc., Pfizer, Inc., and Refuge Biotechnologies.

CIR Workshop Home

Cancer Immune Responsiveness Workshop Schedule

Membership Links

Get Involved